Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|April 14, 2020
Custom APIs Made with Intelligent Collaboration
Author(s)Pfizer CentreOne
Pfizer CentreOne® is a global CDMO embedded within Pfizer and specializes in small molecule API synthesis.
Custom APIs Made with Intelligent Collaboration
Welcome to Pfizer CentreOne. We’re a global CDMO embedded within Pfizer specializing in small-molecule API synthesis.
We can perform almost any kind of chemistry you need. Working together with our customers, we combine our technical and commercial knowledge with open dialogue to solve challenges.
Our commercial manufacturing capabilities span the requirements of Pfizer’s global small-molecule portfolio. As your CDMO, we harness those resources and look forward to collaborating with you.
Our Kalamazoo, Michigan facility serves your custom API manufacturing needs, with more than one million kilograms of finished API per year.
Our capabilities include:
- Complex organic synthesis
- Fermentation and bioprocessing up to 150,000-liter scale
- Milling and micronizing
- Process optimization and scale-up
- Process industrialization
You can rely on us for high-quality API synthesis, from process development through long-term supply.
Pfizer CentreOne
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.